固本益肠片联合英夫利昔单抗对中重度溃疡性结肠炎疗效及对肠黏膜表皮生长因子受体、三叶因子3表达的影响

Curative effect of Gubenyichang tablet combined with infliximab in the treatment of moderate and severe ulcerative colitis and its influence on the expression of epidermal growth factor receptor and trefoil factor 3 in intestinal mucosa

目的探究固本益肠片联合英夫利昔单抗对中重度溃疡性结肠炎疗效及对肠黏膜表皮生长因子受体(epidermal growth factor receptor,EGFR)、三叶因子3(trefoil factor 3,TFF3)表达的影响。方法选取我院2019年6月~2021年2月收治的82例中重度溃疡性结肠炎患者作为研究对象。以电脑随机数法分为联合组和单药组,每组41例,单药组予以英夫利昔单抗治疗,联合组予以固本益肠片联合英夫利昔单抗治疗。比较2组患者治疗8周后的临床疗效、中医证候评分、肠黏膜指标水平、免疫指标水平、不良反应发生率。结果联合组临床疗效优于单药组(P<0.05);2组治疗后中医证候积分均低于治疗前,且联合组低于单药组(P<0.05);2组治疗后肠黏膜TFF3及EGFR水平均高于治疗前,联合组高于单药组(P<0.05);治疗后2组干扰素-γ(interferon-γ,IFN-γ)水平均高于治疗前,联合组高于单药组(P<0.05);治疗后2组白介素-4(interleukin-4,IL-4)水平均低于治疗前,联合组低于单药组(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论固本益肠片联合英夫利昔单抗治疗中重度溃疡性结肠炎可有效促进肠黏膜EGFR和TFF3表达,疗效显著且安全性良好。

Objective To investigate the curative effect of Gubenyichang tablet combined with infliximab in the treatment of moderate and severe ulcerative colitis and its influence on the expression of epidermal growth factor receptor(EGFR)and trefoil factor 3(TFF3)in intestinal mucosa.Methods A total of 82 patients with moderate to severe ulcerative colitis admitted to our hospital from June 2019 to February 2021 were selected.They were divided into combination group(treated with infliximab combined with Gubenyichang tablet)and single infliximab group by computer random number method,with 41 cases in each group.The clinical efficacy,traditional Chinese medicine(TCM)syndrome score,intestinal mucosa index level,immune index level and incidence of adverse reactions were compared between 2 groups after 8 weeks of treatment.Results The clinical efficacy of combination group was better than single drug group(P<0.05).The TCM syndrome score of the 2 groups after treatment was lower than before,and those in combination group was lower than those in single drug group(P<0.05).The levels of TFF3 and EGFR in intestinal mucosa in 2 groups after treatment were higher than before,and those in combination group were higher than those in monotherapy group(P<0.05).After treatment,the level of IFN-γin both groups was higher than before,and that in combination group was higher than that in monotherapy group(P<0.05).After treatment,IL-4 in both groups was lower than before,and those in combination group was lower than those in monotherapy group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Gubenyichang tablet combined with infliximab can effectively promote the expression of EGFR and TFF3 in intestinal mucosa in the treatment of moderate and severe ulcerative colitis,with significant efficacy and good safety.